Moloney Securities Asset Management LLC Cuts Holdings in Allogene Therapeutics, Inc. $ALLO

Moloney Securities Asset Management LLC trimmed its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 9.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 267,500 shares of the company’s stock after selling 27,500 shares during the period. Moloney Securities Asset Management LLC’s holdings in Allogene Therapeutics were worth $302,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new stake in Allogene Therapeutics during the 1st quarter valued at $28,000. R Squared Ltd bought a new position in shares of Allogene Therapeutics during the 2nd quarter valued at $37,000. Brooklyn Investment Group bought a new position in shares of Allogene Therapeutics during the 1st quarter valued at $45,000. Y Intercept Hong Kong Ltd bought a new position in shares of Allogene Therapeutics during the 1st quarter valued at $64,000. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Allogene Therapeutics by 183.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 71,688 shares of the company’s stock valued at $81,000 after buying an additional 46,398 shares during the period. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Stock Performance

Shares of Allogene Therapeutics stock opened at $1.20 on Friday. Allogene Therapeutics, Inc. has a one year low of $0.86 and a one year high of $3.78. The stock’s fifty day moving average is $1.20 and its 200 day moving average is $1.26. The stock has a market cap of $266.26 million, a P/E ratio of -1.08 and a beta of 0.43.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. Analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ALLO. JMP Securities reissued a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Wall Street Zen cut Allogene Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, October 12th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Allogene Therapeutics in a report on Friday. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.44.

Insider Buying and Selling

In other Allogene Therapeutics news, CFO Geoffrey M. Parker sold 36,744 shares of the firm’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $1.26, for a total transaction of $46,297.44. Following the sale, the chief financial officer directly owned 1,276,796 shares of the company’s stock, valued at $1,608,762.96. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 13.20% of the stock is currently owned by corporate insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).